Back to search results

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC) Study

This observational study, called MAGIC, is looking at how two tools – multi-parametric magnetic resonance imaging (MRI) of the prostate and the Genomic Prostate Score (GPS) assay – can help men with prostate cancer decide on their treatment. The GPS assay is a test that looks at 17 genes to help predict if the cancer is aggressive. The study wants to see if these tools can help more men, especially Black men and those in safety net hospitals, choose active surveillance (careful monitoring instead of immediate treatment). You might be able to join if you are a man between 40 and 76 years old, were diagnosed with very low to favorable intermediate risk prostate cancer within the last three months, and are willing to consider active surveillance. The study will measure how many men choose active surveillance prostate biopsy by 18 months after their initial diagnosis. The current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 222 men. It is not a randomized trial.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 18 months after diagnostic prostate biopsy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05424783

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

Active, Not Recruiting
Not specifiedAges 40–76Observational
Northwestern University
~222 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of men who had an active surveillance prostate biopsy by 18 months
Measured over 18 months after diagnostic prostate biopsy

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

2 sites across 1 states
Illinois2

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have NCCN very low to favorable intermediate risk prostate cancer.
Participants must be diagnosed within 3 months prior to study enrollment.
Participants must be male, age 40-76 years old.
Participants must be willing to consider active surveillance for treatment.

Exclusion

Participants with less than 10 years life expectancy.
Participants unable to complete standardized surveys.
Participants with no access to the rectum for a transrectal ultrasound.
Participants with a contraindication to magnetic resonance imaging (MRI).

What this trial measures

  • Proportion of men who had an active surveillance prostate biopsy by 18 months18 months after diagnostic prostate biopsy

    The men in the MAGIC study who chose active surveillance that complete their active surveillance prostate biopsy by 18 months after their diagnostic prostate biopsy will be compared to men who chose active surveillance in the ENACT Clinical Trial who received GPS alone (ENACT intervention arm) or neither GPS nor prostate MRI (ENACT control arm).